regulatory
confidence high
sentiment positive
materiality 0.75
Neuraxis gets FDA 510(k) clearance for PENFS to treat functional dyspepsia in ages 8+
Neuraxis, INC
- FDA cleared Neuraxis' PENFS for functional abdominal pain associated with functional dyspepsia and nausea in patients 8 years and older.
- This is the first FDA clearance or approval specifically addressing functional dyspepsia in adults.
- Clearance based on RCTs and real-world evidence; FDA extrapolated pediatric data to adults.
- Company increased ATM offering from $3.3M to $6.27M; no shares sold under prior agreement.